NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $6.65 -0.06 (-0.89%) Closing price 04:00 PM EasternExtended Trading$6.64 -0.01 (-0.08%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DAWN alerts:Sign Up Key Stats Today's Range$6.43▼$6.7250-Day Range$6.27▼$7.2352-Week Range$6.08▼$16.76Volume1.05 million shsAverage Volume1.27 million shsMarket Capitalization$674.06 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingBuy Company Overview Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. Read More Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 449th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($0.72) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -9.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.77% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 12.06%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.77% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 12.06%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest2 people have searched for DAWN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $167,298.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Stock News HeadlinesDay One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025July 22, 2025 | globenewswire.comDAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More - NasdaqJuly 8, 2025 | nasdaq.comLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.August 1 at 2:00 AM | Stansberry Research (Ad)When Will Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Breakeven?July 1, 2025 | finance.yahoo.comDay One Biopharmaceuticals Inc News (DAWN) - Investing.comJune 24, 2025 | investing.comTimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)June 23, 2025 | msn.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | finance.yahoo.comDay One Appoints Michael Vasconcelles, M.D., as Head of Research and DevelopmentJune 10, 2025 | globenewswire.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $12.67 at the start of the year. Since then, DAWN stock has decreased by 47.5% and is now trading at $6.65. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The company earned $30.76 million during the quarter, compared to the consensus estimate of $30.28 million. Day One Biopharmaceuticals had a negative net margin of 42.66% and a negative trailing twelve-month return on equity of 14.98%. Read the conference call transcript. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Top institutional shareholders of Day One Biopharmaceuticals include Y Intercept Hong Kong Ltd (0.28%), GC Wealth Management RIA LLC (0.08%), CWM LLC (0.02%) and Teacher Retirement System of Texas (0.02%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Papanek Julie Grant, Julie Papanek Grant, Charles N York II, Jeremy Bender, Adam Dubow, Saira Ramasastry and Lauren Merendino. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings5/06/2025Today8/01/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Day One Biopharmaceuticals$29.00 High Price Target$36.00 Low Price Target$25.00 Potential Upside/Downside+342.5%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.50 million Net Margins-42.66% Pretax Margin-38.25% Return on Equity-14.98% Return on Assets-13.04% Debt Debt-to-Equity RatioN/A Current Ratio10.62 Quick Ratio10.55 Sales & Book Value Annual Sales$131.16 million Price / Sales5.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book1.31Miscellaneous Outstanding Shares101,360,000Free Float95,078,000Market Cap$664.31 million OptionableOptionable Beta-1.27 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:DAWN) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredThe Dollar’s Crashing—What Are You Doing About It?The U.S. dollar is down 10.8%—its steepest drop since 1973. As global confidence in the dollar fades, centr...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.